Alkermes plc (ALKS) on Wednesday announced positive topline results from its Vibrance-2 Phase 2 study evaluating alixorexton in patients with narcolepsy type 2 (NT2). Shares rose more than 7% in pre-market trading.
NT2 is a rare, chronic neurological sleep disorder that affects the brain's ability to regulate the sleep-wake cycle.
In Vibrance-2, alixorexton met both primary endpoints, showing statistically significant and clinically meaningful improvements from baseline versus placebo on the Maintenance of Wakefulness Test (MWT) and Epworth Sleepiness Scale (ESS) at week eight. The drug was generally well tolerated at all doses tested.
Alkermes plans to initiate a Phase 3 study of alixorexton in narcolepsy in the first quarter of 2026.
A Phase 2 trial, dubbed Vibrance-3, evaluating alixorexton in idiopathic hypersomnia (IH), is currently ongoing.
Alkermes stock closed at $33.81, up 3.55% on Tuesday.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.